P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

• John Timmerman,
• David Lavie,
• Nathalie Johnson,
• Abraham Avigdor,
• Peter Borchmann,
• Charalambos Andreadis,
• Ali Bazargan,
• Gareth Gregory,
• Colm Keane,
• Inna Tzoran,
• Vladan Vucinic,
• Pier Luigi Zinzani,
• Rachel Marceau West,
• Pallavi Pillai,
• Patricia Marinello,
• Alex F. Herrera

Affiliations

John Timmerman

1 UCLA Medical Center, Los Angeles, United States

David Lavie

2 Hadassah Medical Center, Jerusalem, Israel

Nathalie Johnson

3 Jewish General Hospital, Montreal, Canada

Abraham Avigdor

4 Chaim Sheba Medical Center, Ramat Gan, Israel

Peter Borchmann

5 University Hospital Cologne, Cologne, Germany

Charalambos Andreadis

6 UCSF, San Francisco, United States

Ali Bazargan

7 University of Melbourne, Melbourne, Australia; St Vincent’s Hospital, Fitzroy, Australia

Gareth Gregory

8 School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

Colm Keane

9 Princess Alexandra Hospital, Brisbane, Australia

Inna Tzoran

10 Rambam Health Care Campus, Haifa, Israel

Vladan Vucinic

11 Leipzig University Medical Center, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, Leipzig, Germany

Pier Luigi Zinzani

12 IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

Rachel Marceau West

13 Merck & Co., Inc., Rahway, United States

Pallavi Pillai

13 Merck & Co., Inc., Rahway, United States

Patricia Marinello

13 Merck & Co., Inc., Rahway, United States

Alex F. Herrera

14 City of Hope, Duarte, United States